for growth hormone
99%+ · 10mg · Lyophilized
Bulk discount
3+ pcs
€23.75
−5%
5+ pcs
€22.50
−10%
10+ pcs
€21.25
−15%
Discount is applied automatically at checkout.
🎉 One free — saved €25
Preview: offer goes live at launch.
The catalog is not yet accepting orders. Join the list.
In Stock - Ships within 24 hours
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
CJC-1295 (no DAC)
Short-Acting Growth Hormone Releasing Hormone Analog | Modified GRF 1-29
In short
Modified GHRH analog studied for its ability to stimulate growth hormone secretion in endocrine models.
Best sellers
Education
Related resources
Ready-to-use starter kit
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of the growth hormone-releasing hormone (GHRH). At the molecular level, it binds to specific receptors on somatotroph cells and stimulates the natural, pulsatile release of growth hormone. In laboratory settings (in vitro) and animal models, the molecule is researched for its ability to mimic physiological hormone secretion with a short half-life of about 30 minutes. This product is strictly for research purposes and is not an approved medication or therapeutic agent for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Unlike its DAC-modified counterpart, this version has a brief half-life of approximately 30 minutes, allowing for more precise control over growth hormone pulses and reduced risk of receptor desensitization.
GHRH analog with 4 modifications (30 min half-life) Preserves native GH pulsatile pattern 5-10x amplified GH pulse with ipamorelin (Sigalos 2018) Standard GHRH for IGF-1 axis research
Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses
Stimulates physiological growth hormone pulses that decline with age
Increases insulin-like growth factor 1 levels through enhanced GH secretion
Maintains healthy pituitary-somatotroph axis without suppression
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Morning (upon waking), post-workout (if applicable), 30 minutes before bed
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 5.0
5.0marks
Standard insulin syringe 1 ml (100 marks)
Concentration
5.00mg/ml
Dose volume
0.050ml
U-100 units
5.0units
Doses per vial
40doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (10 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Morning (upon waking), post-workout (if applicable), 30 minutes before bed
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Injection-site reaction
common
Transient flushing
uncommon
Water retention (mainly DAC version)
uncommon
Mild hunger
uncommon
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Long-term Safety Profile of Modified GRF Analogs (2015)
Animal model | 6 months | Daily administration
No significant adverse effects on pituitary morphology or function with chronic use, supporting the safety of long-term pulsatile GHRH analog administration.
Comparative Analysis: CJC-1295 vs Native GHRH (2010)
In vitro + Human | Various doses | Receptor binding assays
Found CJC-1295 without DAC had 4x greater receptor affinity than native GHRH and enhanced resistance to enzymatic degradation, explaining its superior efficacy.
Growth Hormone Pulsatility with Mod GRF 1-29 (2008)
Human | 100mcg 3x daily | 30 days | 24 subjects
Showed preservation of natural GH pulsatility patterns when administered 3 times daily, with no evidence of pituitary desensitization over the study period.
Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)
Human | 100-200mcg | Single dose | 12 subjects
Demonstrated rapid absorption with peak GH levels at 15-30 minutes post-injection, establishing the short half-life profile and optimal dosing frequency for pulsatile GH release.
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
